1252 results about "Drug treatment" patented technology

This relates to methods and devices for treating reversible chronic obstructive pulmonary disease, and more particularly, relates to a device for exchanging energy with airway tissue such as that found in the airway of human lungs. The exchange of energy with this airway tissue in the airways reduces the ability of the air ways to constrict and / or reduces the resistance within the airway to the flow of air through the airway. This also relates to a method for decreasing responsiveness or decreasing resistance to airflow of airways involves the transfer of energy to or from the airway walls to prevent or reduce airway constriction and other symptoms of lung diseases. The treatment reduces the ability of the airway to contract during an acute narrowing of the airways, reduces mucus plugging of the airways, and / or increases the airway diameter. The methods according to the present invention provide a longer duration and / or more effective treatment for lung diseases than currently used drug treatments, and obviate patient compliance issues. This also includes additional steps that reduce the ability of the lung to produce at least one of the symptoms of reversible obstructive pulmonary disease and to reduce the resistance to the flow of air through a lung.

The present invention provides an endoscope for in vivo imaging the cells, tissue, organs or body cavities of humans or other animals to observe and locate, diagnosis and / or treat disease. Illumination sources, image detectors, sensors may be provided alone or in combination on the removable tip allowing functional alterations or optimization for a particular procedure. Endoscope features such as an instrument channel supporting tissue sampling, suction, treatment, micro-surgery, optical computed tomography, confocal microscopy, laser or drug treatments, injections, gene-therapy, marking, implanting or other medical techniques are maintained.

The invention relates to the extraction and / or presentation of glucose concentrations estimated as a function of time into a format that facilitates conveyance of the underlying information. More particularly, short term actions, such as exercise, diabetes drug treatment, and / or food intake, are correlated to glucose response profiles. Optionally, glucose concentration responses are back correlated to parameters, such as time, exercise, diabetes drug treatment and / or food intake. The resulting correlated data are output to the user in a time compressed format, in video format, and / or as a cluster allowing diagnosis and treatment information to be more readily determined and used. These information presentations are useful for both the medical professional and the end user. The information presentation is preferably used with a noninvasive, implantable, semi-continuous, and / or continuous analyte analyzer, such as a glucose concentration analyzer.

Personalized medicine involves the use of a patient's molecular markers to guide treatment regimens for the patient. The scientific literature provides multiple examples of correlations between drug treatment efficacy and the presence or absence of molecular markers in a patient sample. Methods are provided herein that permit efficient dissemination of scientific findings regarding treatment efficacy and molecular markers found in patient tumors to health care providers.

The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. The method of the invention includes the step of determining the level of one or more 6-mercaptopurine metabolites in the patient having an immune-mediated gastrointestinal disorder.

This is a surgical device usually delivered through an intravascular catheter. It may be used in several ways. It may, for instance, be used to open a clear passageway adjacent thrombus to allow both blood and medication to bypass the clot. It may be used to pierce and to remove thrombus. These thrombus are often found in tortuous vasculature. The device includes several sections. The device has a core element, typically a core wire. Placed around the distal end of the core element is a collapsible but preferably self expanding proximal cage assembly and a distal filter, preferably a self-expanding cage assembly or other filter component. The various portions of those components are preferably radio-opaque. The proximal end of the proximal cage is typically is affixed to an actuator in such a way as to allow expansion of the cage after deployment. The proximal cage assembly may be used for collecting emboli or for displacing them to allow blood flow to resume, either with or without concurrent clot-dissolving drug treatment. The distal sector, whether a self-expanding cage or fan, is placed distally of the thrombus to collect portions of the thrombus which may loosen during the treatment or removal procedure.

Disposable dental mouthpiece-strip which has been pre-impregnated with dental substance which can either be placed in the mouth by the user or inserted in the mouth by a dentist for oral treatments, such as teeth whitening treatments, fluoride treatments, or medical treatments, such as the application of anasthetic or antimicrobal / antiseptic treatments. The mouthpiece-strip is made with a foldable structure such as a thin strip of wax with a section of porous material (sponge) that holds the treatment dental product (liquid or gel). The mouthpiece-strip is disposable; the amount of time it is worn is determined by the type of dental treatment. The mouthpiece-strip may be adjusted in size by cutting it with scissors. The wax used for the mouthpiece is non-toxic and allows for a perfect adjustment in the mouth by contouring to the teeth during adjustment by the user. To enhance the fit in the mouth, the inner surface of the mouthpiece-strip may contain a thin layer of non-toxic sticky adhesive. The porous (sponge) strip attached to the wax strip is an inert, nontoxic material which is easy to process and inexpensive. It is attached to the wax strip with a non-toxic adhesive.

An emergency system for treatment of a patient (20) experiencing an acute vascular obstruction, employing a non-invasive vibrator (10), optimally in conjunction with drugs, for disrupting and lysing thromboses, relieving spasm (if associated), and thereby restoring blood perfusion. Vibrator (10) is operable in the sonic to infrasonic range, with a source output of up to 15 mm. For acute myocardial infarction cases, a pair of contacts (12), are advantageously placed to bridge the sternum at the fourth intercostal space. Vibration is initiated at 50 Hz (or any frequency, preferably within the 20-120 Hz range), and is ideally adjusted to a maximal amplitude (or force) deemed tolerable and safe to the patient (20), preferably with the administration of thrombolytic agents or other form of drug therapy. A synergistic effect is achieved between vibration and drugs to facilitate the disruption of thromboses, relieve spasm, and restore blood perfusion. In a variation, ultrasonic imaging may be used to direct vibration therapy.

This relates to methods and devices for treating reversible chronic obstructive pulmonary disease, and more particularly, relates to a device for exchanging energy with airway tissue such as that found in the airway of human lungs. The exchange of energy with this airway tissue in the airways reduces the ability of the air ways to constrict and / or reduces the resistance within the airway to the flow of air through the airway. This also relates to a method for decreasing responsiveness or decreasing resistance to airflow of airways involves the transfer of energy to or from the airway walls to prevent or reduce airway constriction and other symptoms of lung diseases. The treatment reduces the ability of the airway Lo contract during an acute narrowing of the airways, reduces mucus plugging of the airways, and / or increases the airway diameter. The methods according to the present invention provide a longer duration and / or more effective treatment for lung diseases than currently used drug treatments, and obviate patient compliance issues. This also includes additional steps that reduce the ability of the lung to produce at least one of the symptoms of reversible obstructive pulmonary disease and to reduce the resistance to the flow of air through a lung.

Disclosed is an extended or controlled release dosage form of citalopram or its related forms and other newer antidepressants for oral administration to treat chronic patients suffering from depression and to minimize the side effects associated with the current drug treatment.

An eyewear apparatus for treating dry eye conditions featuring a pair of curved eyecups having interior cavities for providing treatment to the eyes when worn. Each interior cavity has a sidewall surface adapted to removably engage with the perimeter edge of a moisture pad which may be mounted therein to provide moisture, aroma, or medicinal treatment to the eye. An ocular cavity formed in the moisture pads provides a separate treatment chamber to each of the two eyes of a user. Heat or cold may also be provided to the ocular chamber through temperature components which mount to the moisture pad or in a gap between the moisture pad and the front of the interior cavity.

A dosage form is disclosed comprising means for delaying the delivery of drug from the dosage form following the administration of the dosage form to a patient in need of drug therapy.

A computer-implemented system and method analyzes the effectiveness of pharmaceutical treatments for medical conditions utilizing real time prescription compliance records. Information related to medical history of a patient can be reviewed while simultaneously reviewing prescription compliance records for the same patient. Trends in a target or non-target medical parameter can be identified and correlated with the prescription compliance records to determine the effectiveness of a pharmaceutical treatment on the target and non-target medical parameter. Correlations can be identified for a group of patients having the same medical condition.

An embodiment of the present invention is a method for measuring activity of cell pathways, such as the cell cycle pathway and correlating the resulting profile to phenotypes. The resulting correlations are useful in diagnosis, prognosis, selection and development of drug treatment regimens, and drug screening applications.

An efficient, objective testing method and system for evaluating changes in mental function is described. The method and system are based on measuring an individual's behavioral responses and brain function during a brief cognitive test battery and passive control conditions. The method and system is designed to assess an individual's fundamental cognitive functions, and whether those functions have been significantly affected by a variety of factors such as progressive disease processes, medication, stress, fatigue, training, or the passage of time. The method and system can be used to determine whether drugs being evaluated to treat diseases or conditions affecting cognitive brain function have a significant positive effect on delaying or improving the symptoms of such a disease or condition, especially during clinical trials for drug approval and subsequent marketing. The method and system may also be employed as part of the successful diagnosis or ongoing treatment of neurological diseases or conditions that directly or indirectly affect human neurocognitive performance. The method and system may also be used to determine transitory changes in overall cognitive function due to emotional stress or fatigue, and more long lasting changes in overall cognitive function following training and educational programs.

The present disclosure generally pertains to systems and methods for drug compliance monitoring. A drug compliance monitoring system in accordance with one exemplary embodiment of the present disclosure comprises a portable drug containment unit, which has a drug container, such as a pill bottle, for holding prescription or non-prescription drugs. The drug containment unit also comprises at least one sensor and control logic. The sensor is configured to automatically sense a parameter indicating when a drug, such as one or more pills or an amount of liquid, has been or is about to be removed from the drug container. The system, based on the sensor, automatically estimates and tracks drug consumption and provides a patient with reminders when a dosage is currently due. If the patient deviates from an expected drug regime, the system automatically senses this event and provides a notification to the patient or caregiver. In addition, the system stores a usage history indicating the approximate time and amount of each sensed dosage.

Methods for monitoring subject compliance with a prescribed treatment regimen are disclosed. In one embodiment, the method comprises measuring a drug level in fluid of a subject and normalizing said measured drug level as a function of one or more parameters associated with the subject. The normalized drug level is compared to a reference value and associated confidence intervals or to a concentration range. The reference value and associated confidence intervals and / or the concentration range may be normalized based on one or more parameters associated with subjects in a reference population.

Real-time and individualized disease monitoring is central to rapidly evolving medical sciences and technologies, but for the vast majority of patients, disease progression and treatment are monitored only in an irregular and discontinuous fashion. Consequently, disease progression and relapse are often allowed to proceed too far before they are detected, compromising the possibility of any effective treatment. For one patient, this can mean becoming refractory to the few early drug treatments that are available; for another, missing early detection may be deadly. This invention provides a method for the detection of early signals of disease and recovery thereof comprising a universal yet personalized health-monitoring solution using cell phones or other wearable smart device data that generate extensive real-time data. The invention further provides a system and method to provide answers to a variety of questions related to the patient health status and health trajectory. Its flexibility and generality is designed for a preferred application to rare disorders and rare questions for which other analytical system are lacking.

The invention provides a method, and dosage form therefor, of treating impaired motor function associated with Parkinson's disease, anti-Parkinson's drug treatment, e.g. L-Dopa therapy, and / or dementia associated with Parkinson's disease. The invention includes the combined administration of an NMDA receptor antagonist and an antidepressant, e.g., the combination of amantadine and citalopram or venlafaxine, or an NMDA receptor antagonist and an anxiolytic agent, e.g., amantadine and buspirone or trazodone, for the amelioration of undesired tremors, akinesia, dyskinesia, or bradykinesia associated with one or more different disorders or diseases. The drugs can be included in a single dosage form. One embodiment includes a combination dosage form containing each drug in controlled release forms. Another embodiment includes a combination dosage form providing a controlled release of an NMDA receptor antagonist and a rapid release of a neuroactive agent after administration to a subject.

This invention provides methods for detecting and predicting drug interaction. In one embodiment of the invention, a plurality of cellular constituents in a biological sample is monitored as the sample is subject to various drug treatments. The response of the cellular constituents are analyzed to detect interactions. This method is particularly useful for predicting drug interaction using a model organism. It is also useful for analyzing interaction between any perturbations to a biological system.

The invention relates to an apparatus, system and method for managing medication. In particular, the invention relates to adaptable pill organizer. The adaptable pill organizer comprises of at least one or more rectangular units for containing pills. Individual units and / or rows of seven units, wherein one unit corresponds to the days of the week, attach and detach from one another in order to create a custom pill organizer. The adaptable pill organizer further employs electronic capabilities which: allow user to input, store and display information on the pill organizer; provide lighting means for the device; provide various automatic and / or commanded physical responses to usage of the device such as the lighting of a unit, or the opening and closing of a unit; provide programmed alarms; communicate data messages and usage information with third party devices; and store and provide access to user medication and medication schedule information. The invention further relates to a system and method for managing a self medication regime which works in conjunction with an electronic adaptable pill organizer, a third party device, or a combination thereof, in order to provide the aforementioned capabilities within the electronic pill organizer. The system further allows a third party device to receive, and transmit messages to and from an electronic pill organizer in real. The system provides a means and a method for monitoring the usage of an electronic pill organizer by a third party.

A pharmaceutical pig is used to transport a syringe containing a liquid radiopharmaceutical from a radiopharmacy to a medical facility for administration to a patient. The used syringe is sent back in the pig to the radiopharmacy for disposal. The pig includes a cap that is removably attached to a base. Shielding elements, typically formed from lead, are enclosed in the cap and the base. The pig can be used to transport a conventional syringe or a safety syringe. The pig can be used with or without an inner liner in the base. There is never an inner liner in the cap.

The present invention is directed to mutants of HCV NS3 / 4A protease. More particularly, the present invention identifies mutant of HCV NS3 / 4A protease that are resistant to drug treatment.

A method for the treatment of Restless Leg Syndrome (RLS), which comprises administering an alpha2-agonist and a second agent selected from the group consisting of the dopamine agonists, opioids, benzodiazepines and the combination of L-DOPA plus a decarboxylase inhibitor.

A system for monitoring compliance with a medication regimen comprises a patch. The patch includes an RFID apparatus and a sensor. The patch is configured to be removably securable to a body of a biological organism. The sensor is in electrical communication with the RFID apparatus and is configured to inspect a biological material of a biological organism for the presence of a detectable agent. The RFID apparatus is configured to communicate a result of the inspection to an RFID transceiver and / or a communication device. Methods are also provided.

A minimally invasive method of performing mitral annuloplasty is disclosed. An implantable device is positioned within the coronary sinus and tightened around the mitral annulus. Mitral valve regurgitation is monitored before, during, and / or after the tightening step. An on-going drug therapy may be determined, taking into account post-implantation hemodynamic function.

The present invention provides methods for enhanced detection of biological response profiles. In particular, the methods of this invention allow for the detection of biological response patterns, such as gene expression patterns, in response to different drug treatments. The methods of the invention also allow the determination of a "consensus profile" which describes a particular class or type of biological response. In certain embodiments the consensus profile may describe the biological response of a particular group or class of drugs. In other embodiments, the consensus profile may describe an "ideal" biological response such as one associated with a desired therapeutic effect. The methods of the present invention also allow for the comparison of different biological responses. Thus, the methods of the invention may be used, e.g., to identify and / or study new drugs.

A method for treating a patient using an antidiabetic drug, said method comprising administering to the patient a high dose of the antidiabetic drug wherein said antidiabetic drug exhibits one or more dose proportional pharmacokinetic parameters is described.

The invention discloses an artificial intelligence auxiliary diagnosis and treatment system and a construction method thereof, equipment and a storage medium and belongs to the technical field of lifehealth. The system includes a disease knowledge map module, a disease diagnosis model module and a machine learning decision module, wherein the disease knowledge map module is configured to collectvarious resources about diseases and form a disease knowledge database for querying and reading, the disease diagnosis model module is configured to receive the patient information, store the information in the system database, input the information to the machine learning decision module, extract indicator data from the disease knowledge map module through the machine learning decision module toperform comparative analysis, push a patient information set and suggest an examination which a patient needs to take and a scheme set of related drug treatment for choose of doctors. The system is advantaged in that the underlying knowledge map is comprehensive and authoritative, interaction operation is simple, use efficiency is high, on the human-computer interaction level, the intelligence degree is high.

Use of cereblon-associated proteins as biomarkers for clinical sensitivity to cancer, inflammatory diseases, and patient response to drug treatment.